LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

European Funding to Advance Development of Prostate Cancer Drug

By LabMedica International staff writers
Posted on 06 Sep 2015
Print article
The development of a drug for treatment of prostate cancer has been given a boost by the recent award of a EUR 2.5 million grant to its Dutch biopharmaceutical company developer.

The drug developer, Oncodrone (Nijmegen, The Netherlands), has received a grant totaling EUR 2.5 million, which will enable it to advance its lead product, the prostate cancer drug OCD155, through preclinical development towards clinical trials and for further research into its mechanism-of-action.

OCD155 halts tumor progression by blocking epithelial to mesenchymal transition (EMT) in cancers. In the EMT process epithelial cells lose their cell-cell adhesion and develop into cancer cells with aggressive properties. Consequently, cancer cells can escape the original tumor into blood and lymphatic vessels and colonize other tissues. By blocking EMT, the cancer cell is prevented from gaining invasive and malignant properties and becomes less aggressive. OCD155 was shown to be effective in in-vivo laboratory experiments to reduce the ability of tumors to spread, reduce the tumor burden, and treat advanced stages of disease.

The grant to Oncodrone comes from the Eurostars (Brussels, Belgium) and EUREKA (Brussels, Belgium) joint program. Eurostars supports international innovative projects led by research and development-performing small- and medium-sized enterprises. EUREKA is an intergovernmental organization for pan-European research and development funding and coordination. EUREKA aims to coordinate efforts of governments, research institutes, and commercial companies concerning innovation. It does not partake in military research and follows a "bottom-up" approach to research and development funding, industry itself deciding which projects should be developed.

Henk Viëtor, CEO of Oncodrone, said, “I am delighted about this crucial grant that allows us to further develop our novel approach to treating prostate cancer towards testing in humans.”

Related Links:

Oncodrone
Eurostars
EUREKA


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more